


PF-06380101-d₈

Cat. No.:	HY-12522S
Molecular Formula:	C ₃₉ H ₅₄ D ₈ N ₆ O ₆ S
Molecular Weight:	751.06
Target:	Microtubule/Tubulin; ADC Cytotoxin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton; Antibody-drug Conjugate/ADC Related
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 35 mg/mL (46.60 mM); ultrasonic and warming and heat to 60°C			
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg
				5 mg
				10 mg
				10 mg
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.33 mg/mL (3.10 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.33 mg/mL (3.10 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.33 mg/mL (3.10 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	PF-06380101-d ₈ is a deuterium labeled PF-06380101. PF-06380101, an Auristatin microtubule inhibitor, is a cytotoxic Dolastatin 10 analogue[1].
IC ₅₀ & Target	Auristatin

CUSTOMER VALIDATION

-
- J Chromatogr B. 2023 Jun 15, 123786.
 - J Chromatogr B. 2023 Apr 9,123715.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Maderna A, et al. Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J Med Chem. 2014 Dec 26;57(24):10527-43.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA